Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Antiretroviral therapy in the private sector of Nairobi, Kenya: a review of the experience of five physicians.

Macharia DK, Chang LW, Lule G, Owili DM, Tesfaledet G, Patel S, Silverstein DM, Ng'ang'a L, Bush T, De Cock KM, Weidle PJ.

AIDS. 2003 Apr 11;17(6):938-40. No abstract available.

PMID:
12660550
2.

Should physicians withhold highly active antiretroviral therapies from HIV-AIDS patients who are thought to be poorly adherent to treatment?

Sollitto S, Mehlman M, Youngner S, Lederman MM.

AIDS. 2001 Jan 26;15(2):153-9. Review. No abstract available.

PMID:
11216922
3.

Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa.

Katende-Kyenda NL, Lubbe MS, Serfontein JH, Truter I.

J Clin Pharm Ther. 2008 Aug;33(4):393-400. doi: 10.1111/j.1365-2710.2008.00930.x.

PMID:
18613857
4.

European HIV/AIDS case reporting: assessing past treatment history in individuals who develop AIDS in the era of highly active antiretroviral therapy.

Semaille CH, Downs AM, Hamers FF; EuroHIV Steering Group.

AIDS. 2003 Jan 24;17(2):270-2. No abstract available.

PMID:
12545092
5.

Antiretroviral therapy in the private sector of resource-limited settings.

Livesley N, Morris CN.

AIDS. 2004 Feb 20;18(3):581-2. No abstract available.

PMID:
15090821
6.

Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative.

Laurent C, Meilo H, Guiard-Schmid JB, Mapouré Y, Noël JM, M'Bangué M, Joko A, Rozenbaum W, Ntoné FN, Delaporte E.

Clin Infect Dis. 2005 Jul 1;41(1):108-11. Epub 2005 May 17.

PMID:
15937770
7.

Stopping antiretroviral therapy: easier said than done.

Hull M, Harris M, Montaner JS.

AIDS. 2007 Aug 20;21(13):1817-8. No abstract available.

PMID:
17690582
8.

Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study.

Lucas GM, Chaisson RE, Moore RD.

J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):321-8.

PMID:
12843742
9.

HIV treatment interruptions: a review.

Newcomb-Fernandez J.

Res Initiat Treat Action. 2003 Fall;9(2):5-13. No abstract available.

PMID:
14989199
10.

Supervised interruptions of antiretroviral therapy.

Deeks SG, Hirschel B.

AIDS. 2002;16 Suppl 4:S157-69. Review. No abstract available.

PMID:
12699013
11.

Scaling-up highly active antiretroviral therapy (HAART) in Peru: problems on the horizon.

Echevarría J, López de Castilla D, Seas C, Verdonck K, Gotuzzo E.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):625-6. No abstract available.

PMID:
17133214
12.

Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.

Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S.

Pediatrics. 2007 Oct;120(4):e856-61. Epub 2007 Sep 10.

PMID:
17846147
13.

The good, the bad, and the ugly: providing highly active antiretroviral therapy when it is most difficult.

Flanigan TP, Mitty JA.

Clin Infect Dis. 2006 Jun 1;42(11):1636-8. Epub 2006 Apr 28. No abstract available.

PMID:
16652322
14.

Adherence in antiretroviral therapy: a review of qualitative studies.

Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH.

AIDS. 2007 Jan 30;21(3):271-81. Review. No abstract available.

PMID:
17255734
15.

Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.

Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, Clevenbergh P, Wit FW, Waalberg E, Rinke de Wit TF, Lange JM; Cohort Program to Evaluate Access to Antiretroviral Therapy and Education Project Team.

J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):262-7.

PMID:
17146376
16.

[HIV-infection: modern antiretroviral therapy].

Rockstroh JK, Spengler U.

Dtsch Med Wochenschr. 2004 Sep 10;129(37):1921-4. Review. German. No abstract available.

PMID:
15372371
17.

Stopping antiretroviral therapy.

Taylor S, Boffito M, Khoo S, Smit E, Back D.

AIDS. 2007 Aug 20;21(13):1673-82. Review. No abstract available.

PMID:
17690564
18.

[Late antiretroviral therapy and ephemeral efficacy].

Muñoz Sanz A.

Med Clin (Barc). 2006 Jul 8;127(6):237; author reply 237. Spanish. No abstract available.

PMID:
16938249
19.

When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies.

Phillips AN, Lepri AC, Lampe F, Johnson M, Sabin CA.

AIDS. 2003 Sep 5;17(13):1863-9. Review. No abstract available.

PMID:
12960818
20.

Symptomatic HIV viraemia during a drug holiday: an argument against treatment interruption?

Freedman E, Dhaliwal K, Estcourt C, Baily G.

Int J STD AIDS. 2004 Aug;15(8):564-5.

PMID:
15307970

Supplemental Content

Support Center